News

MRL Ventures, a venture fund of Merck, and JAFCO led the Series C preferred stock financing round. Brace Pharma Capital and MP Healthcare Venture Management were the other

US-based Ocata develops and commercializes regenerative ophthalmology therapeutics. The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology programs and involve development of therapies to treat

Cotellic and Zelboraf are not used to treat melanoma with a normal BRAF gene. Cotellic is Genentech’s seventh new medicine approved by the FDA in the past five

As company spokesperson, Michael Thompson, noted, Nitrosolution first launched its original nitric oxide booster product Nitroxyl about 2 years ago. While Nitroxyl is designed for people over the

This study is a collaborative effort between MediciNova and Drs. Nazem Atassi and Haruhiko Banno, Principal Investigators at Massachusetts General Hospital’s (MGH) Neurological Clinical Research Institute (NCRI) and

Preliminary studies have demonstrated that PraediCareDx can be used to find AML patients who respond to alvocidib. Tolero is currently starting a randomized Phase II biomarker study in

Bullous pemphigoid is known to be associated with increased eotaxin-1 levels in serum and blister fluids. Immune recently started a Phase IIa open label clinical trial in bullous

GSK will increase potential milestone payments to Avalon Ventures from $40m to $50m for each biotech formed. The companies have also formed the seventh out of ten biotechs

The company completed negotiations to operate a significant proportion of the 70-acre Charnwood Campus in Loughborough, England, UK. Almac will occupy the formulation development and analytical testing plants